Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

NEXT STORY
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
PREV STORY
28.51% CAGR , mRNA Vaccines & Therapeutics Market Size, Share, significant growth Rate, Trends 2026 by Brandessence Market Research
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Inventiva Reports First-half 2018 Financial Results and Provides a Corporate Update

 Inventiva Reports First-half 2018 Financial Results and Provides a Corporate Update Cash position at €75.9 ...

author_avatar
NASDAQ Market News

Bioxytran Using Paradigm Changing Vital Sign that Can Measure Real Time Tissue Oxygen Balance in Emergency Medicine

author_avatar
NASDAQ Market News

Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting

HAYWARD, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present new ...

author_avatar
NASDAQ Market News